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Inﬂammation is a double-edged sword presenting a dual eﬀect on cancer development, from one hand promoting tumor
initiationandprogressionandfromtheotherhandprotectingagainstcancerthroughimmunosurveillancemechanisms.Cytokines
are crucial components of inﬂammation, participating in the interaction between the cells of tumor microenvironment. A
comprehensive study of the role of cytokines in the context of the inﬂammation-tumorigenesis interplay helps us to shed light
in the pathogenesis of cancer. In this paper we focus on the role of cytokines in the development of genomic instability, an evolving
hallmark of cancer.
1.Introduction
Contemporary approaches in cancer research have been
inﬂuenced by the accumulating data unveiling the impor-
tance of inﬂammatory components in the tumor microenvi-
ronment. It is becoming more clearly evident that inﬂamma-
tion demonstrates a dualism eﬀect on cancer development in
close resemblance to a ying-yang pattern. Inﬂammation may
exhibit either a pro- or an antitumorigenic eﬀect. Cytokines
possess a central role in the inﬂammatory component impli-
cated in the interplay between the host’s stromal cells and the
tumor cells during tumorigenesis. In this paper we are shed-
ding light on the molecular pathways linking cytokines with
the induction of genomic instability, an evolving hallmark of
cancer.
2. Interrelationof Inﬂammation
andCarcinogenesis
Rudolf Virchow was the ﬁrst to observe, back in the nine-
teenth, the presence of leukocytes inside tumors and this
observation was the ﬁrst indication of a possible linkage
between inﬂammation and cancer. The last decade intensive
research has focused on the molecular pathways involved in
the above linkage and it is now well understood that chronic
inﬂammation plays a signiﬁcant role in the carcinogenesis
process [1].
In 1909, Paul Ehlrich proposed the immunosurveillance
theory, later established by Thomas and Burnet, which sup-
ports the tumor suppressive role of the immune system [2–
4]. Dunn and his colleagues suggested in 2004 that a
new theory should be adopted to describe the relationship
between the immune response and tumorigenesis, called
immunoediting [5]. According to this theory, three distinct
stages exist describing the interrelation between immunity
and carcinogenesis. The ﬁrst stage, termed elimination, rep-
resents the period in which the immune system, through
successful immunosurveillance, destroys precancerous and
cancerous cells. In equilibrium, the second stage, cancer cells
have begun to develop abilities to avoid immunosurveillance
mechanisms but the balance between “immune patrol” and
tumorigenesis is still preserved. In the third stage, named2 Journal of Biomedicine and Biotechnology
escape, the cancer cells manage to evade the surveillance
system of the organism, resulting in aberrant cell prolifera-
tion and tumor development. Interestingly, it seems that the
immune response to the tumor causes an “immunosculpt-
ing” eﬀect on cancer cells that enables them to resist immu-
nological recognition or to exert enhanced defense mecha-
nisms against immunosurveillance [5].
Recent advances in cancer biology research have demon-
strated that a chronic indolent inﬂammation environment
harbors potential tumor promoting mechanisms [1]. Ac-
cordingtoHanahanandWeinberg, oneofthe emerginghall-
marks of cancer is the ability to escape immunosurveillance
and an enabling characteristic for the acquisition of these
capabilitiesistheinﬂammationpropagatedbythetumor[6].
Compelling evidence of the last decade supports the notion
that the inﬂammatory microenvironment is important for
thesurvivaloftumors[1].Itseemsthatinﬂammatorycellsof
the innate immunity usually display a tumor promoting role
whereas cells of adaptive immunity appear to have a tumor
suppressive eﬀect [1, 7].
Inadequate pathogen eradication or continuous expo-
sures to chemical carcinogens preserve a chronic inﬂam-
mation environment that may enhance tumorigenesis [8].
There is evidence supporting that several unresolved inﬂam-
matory reactions following persistent pathogen infection
promote human malignancies [9]. Pathogens contain spe-
ciﬁc patterns, known as pathogen-associated molecular
patterns (PAMPs), which are recognized by host receptors,
named pattern recognition receptors (PRRs), including Toll-
like receptors (TLRs), nucleotide-binding oligomerization
domain-like receptors (NOD-like) receptors, C-type lectin
receptors (CLRs), and triggering receptors expressed on
myeloid cells (TREMs) [10, 11]. The binding between
PAMPs and PRRs leads to inﬂammation-related cell activa-
tion and triggers host immune defense mechanisms against
foreign pathogens [10]. In relation to the previous part, it
is well established that chronic viral hepatitis B and C is
strongly associated with the development of hepatocellular
carcinoma. In this case, excessive host reaction towards the
viral infection is believed to play a signiﬁcant role for the
inﬂammation-mediated liver carcinoma. On the other hand
and not mutually exclusive there are several viral infections
in which the virus itself through its oncogenic potential is
mainly responsible for the cancer development [12]. Human
Papilloma Virus (HPV) infection is associated with cervical
cancers and Epstein-Barr infection bears signiﬁcant associa-
tionwithBurkittlymphomaandnasopharyngealcarcinoma.
Particular types of HPV produce the E6 and E7 oncoproteins
which interfere with the p53 and Retinoblastoma protein
(pRb)pathways,respectively.Epstein-Barrvirus(EBV)latent
membrane protein 1 (LMP1) is critical for EBV-induced
cellular transformation through the activation of NF-κB
(analyzed hereinafter), a transcription factor promoting cell
survival [13].
In the context of chemically induced carcinogenesis, a
typical example involves cigarette smoking, in which the
tumorigenic activity is partially attributed to its ability to
induce chronic inﬂammation [14]. Also asbestos or sil-
ica exposure may cause inﬂammation of the lung and
subsequent bronchial carcinoma [15]. The mechanism of
the induced inﬂammation by the above inhaled particles
occurs by means of prointerleukin-1β (IL-1β) processing by
the inﬂammasome [1, 16]. The inﬂammasome is a protein
complex which includes two caspase-1 molecules, is related
to cryopyrin protein, and leads to IL-1β cross-activation and
maturation [17].
3.CellularContextandCytokineSignalingin
the Tumor Microenvironment
The cellular context of the tumor’s microenvironment
includes cancer cells and surrounding stromal cells (involv-
ing ﬁbroblasts, endothelial cells, pericytes, and mesenchy-
mal cells) along with the inﬁltrating cells of the innate
and adaptive immunity [1]. Innate immune cells include
macrophages, myeloid-derived suppressor cells (MDSCs),
neutrophils, and mast, dendritic, and natural killer (NK)
cells, while adaptive immune cells consist of T and B lym-
phocytes. The only immune cells with no known tumor
promoting role to date are NK cells [1]. MDSCs share
common characteristics with macrophages, neutrophils, and
dendritic cells and they help in tumor angiogenesis as well
as suppression of antioncogenic immune responses [18,
19]. Tumor-associated macrophages (TAMs) and T cells are
among the most frequently observed cells within the tumor
microenvironment. TAMs are a heterogeneous cell popula-
tion which evidently exerts a very signiﬁcant role in tumor
cell survival, growth, and progression and can be considered
obligate partners for tumor cell migration, invasion, and
metastasis [20, 21].
The interaction between the epithelial and stromal cells
comprising the inﬂammatory microenvironment is medi-
ated by a class of molecules named as cytokines. Cytokines
are cell-signaling protein molecules with eﬀects on inter-
cellular communication; they include interleukins, lym-
phokines, and chemokines. Interleukins were initially
observed to be expressed by leukocytes and present im-
munoregulatory action. Lymphokines are produced by lym-
phocytes and include IL-2, IL-3, IL-4, IL-5, IL-6, GMC-SF
(Granulocyte-macrophage colony-stimulating factor), and
IFN-γ (Interferon-gamma). Chemokines are chemoattrac-
tant cytokines and are named this way due to their ability to
control leukocyte migration to inﬂammation sites through
chemotaxis [22, 23]. The nomenclature of chemokines is
basedonthenumberand locationof theN-terminalcysteine
residues, divided in four diﬀerent groups: CXC, CC, CX3C,
a n dC[ 23].
In accordance with increased expression of pro- or anti-
inﬂammatory cytokines and to tumor progression, TAMs
may be classiﬁed into M1 and M2 types. M1 macrophages
are mostly found in early stage tumor development and
may release proinﬂammatory cytokines (TNF-a, IL-1, IL-6,
IL-12, IL-23) and chemokines CXCL19 and CXCL10. Their
physiological role involves Th1/Th17 cellular responses and
NK cell development and diﬀerentiation. M2 macrophages
may be mostly found in more established tumors, show
increased expression of IL-10 and transforming growthJournal of Biomedicine and Biotechnology 3
factor β (TGF-β) as well as chemokines CCL17, CCL22, and
CCL24, and are considered to promote tumor angiogenesis.
This subtype of TAMs encourages Th2 and regulatory T
cells (Tregs) recruitment [1, 7]. According to their eﬀector
functions,TcellscanbesubdividedinCD8+cytotoxicTcells
(CTLs) and CD4+ helper T (Th) cells, including Th1, Th2,
and T regulatory (Treg) cells [1]. T cells may exhibit either
antitumor immune responses or promote tumor growth
[1, 24].
The mechanisms of inﬂammation-mediated tumor pro-
motion involve secretion of speciﬁc cytokines by both
inﬂammatory and tumor cells as well as activation of tran-
scription factors, mainly (Nuclear Factor-κB) NF-κB, (Signal
Transducers and Activators of Transcription) STAT3, and
(ActivatorProtein-1)AP1.NF-κBandSTAT3expressioncan
be detected in most cancers and these transcription factors
activate genes responsible for cell survival, proliferation,
angiogenesis, invasiveness, and production of cytokines [1,
25, 26]. NF-κB belongs to a family of transcription factors
that regulate the secretion of many inﬂammatory cytokines,
speciﬁc adhesion molecules, and the prostaglandin biosyn-
thetic pathway. It also regulates the expression of antiapop-
totic proteins and angiogenic factors in a tissue-speciﬁc
manner [15, 27]. There are three distinct activation pathways
of NF-κB, the classical, the alternative, and the atypical
pathways,andallseemtosupporttumorigenesis[18,28,29].
The classical pathway is triggered by pathogen infection,
T-cell receptor (TCR) engagement, and proinﬂammatory
cytokines, such as IL-1 and TNF-α [28, 29]. The NF-κB
alternative pathway is triggered by cytokines belonging to
the TNF family and involves the IKKα homodimer and the
p52/RelB transcription factors [18, 28]. Finally, the atypical
NF-κB pathway is IKK independent and is triggered by
several stimuli such as hypoxia and hydrogen peroxide attack
of the cells [29]. STAT3 activation induces the expression
of Bcl2 and Bcl-xL antiapoptotic genes, Cyclin D1 or c-
Myc proliferation genes, and VEGF (vascular endothelial
growth factor) angiogenesis promoting gene [18, 27]. AP-
1 is a dimeric transcription factor composed of members
of the Jun, Fos, activating transcription factor (ATF) and
musculoaponeurotic ﬁbrosarcoma (Maf) protein families.
Several growth factors and cytokines induce MAPK sig-
nalling pathway which in turn activates AP-1 [30].
Cytokine IFN-γ most frequently produced by cytotoxic
CD8+ and CD4+ Th1 T cells has been recognized as a
dominant tumor-inhibitory force (Table 1). On the other
side, the cytokines interleukin-6 (IL-6), TNF-α,I L - 1 β,
and IL-23 are mostly considered as tumor promoting [7].
Secretion of the latter cytokines is mainly induced by tumor
associated macrophages and myeloid-derived suppressive
cells [7]. One of the previously mentioned cytokines,
macrophage-derived IL-1, was indicated to promote both
inﬂammation and angiogenesis under a hypoxic environ-
ment which in turn ascertains the important role of IL-1
in inﬂammation-mediated tumorigenesis [31]. Additionally,
IL-1β has recently been shown to induce a subset of MDSC
in the tumor microenvironment capable of suppressing the
development and function of NK cells [32]. Proinﬂam-
matory cytokines include IL-2, IL-6, IL-11, IL-15, IL-17,
IL-23, TNF-α, and chemokine IL-8 and anti-inﬂammatory
cytokines include IL-4, IL-10, IL-13, transforming growth
factorβ (TGF-β)andinterferon(IFN)-α[22,33].Proinﬂam-
matory cytokines, such as IL-1 and TNF-α which in turn
stimulate IL-8, may also stimulate chemokines [22, 34].
An interesting example of cytokine-mediated carcino-
genesis is human malignant mesothelioma which may be
provoked by chronic exposure to asbestos. TNF-α displays a
tumor promoting role in this type of cancer by helping the
survival of the mesothelial cells which, in turn, have been
damaged by asbestos exposure and may develop mutagenic
phenotypes rendering them susceptible to carcinogenesis
[10,35].TNF-αfavorsthesurvivaloftumorcellsbyinducing
the expression of antiapoptotic genes encoded in an NF-κB-
dependent manner [10]. As a result, TNF-α—which may
be released by host as well as cancer cells—signiﬁcantly
inﬂuences the initiation and progression stages of all cancer
types [10]. Similarly, IL-6 exerts a tumor promoting role by
enhancing cell cycle progression and suppressing apoptosis.
Its signaling transduction pathway is induced by STAT3
transcription factor [10, 21]. IL-17 triggers the secretion of
TNF-α, IL-6, and IL-1β proinﬂammatory cytokines and is
produced by IL-23-dependent STAT3 activation [10, 36]. IL-
23 has similar functions to IL-17, induces IFN-γ,a n dI L -
12 production by activated T cells, and leads to enhanced
proliferation of memory T cells [10, 37]. IL-10 activates
STAT3 transcription factor but has an opposite eﬀect in
carcinogenesis to IL-6 [10]. Additionally it inhibits NF-κB
activation and in this manner also inhibits production of
TNF-α, IL-6, and IL-12 [10, 38]. IL-10 probably exhibits
its tumor suppressive role by inhibiting the production of
the above mentioned proinﬂammatory cytokines [10]. IL-
10 may also exert protumorigenic activity through STAT3
activation by upregulating Bcl2 and Bcl-xL antiapoptotic
genes, therefore conﬁrming its dual role in the process of
carcinogenesis [10, 39]. Other cytokines have a known dual
function in carcinogenesis (Table 1). Interestingly, TGF-β
may exert a tumor suppressive role in the beginning of the
process and a tumor promoting role at the late stages of
carcinogenesis [40].
Lessons for themechanisms implicated in inﬂammation-
associated carcinomas have paradoxically been taken by the
study of cellular senescence [41]. It has been shown that
senescent cells are metabolically active and secrete several
factors that may alter their own as well as the tumor
microenvironment [42]. The phenomenon of such secretion
by the senescent cells has been termed senescence-associated
secretory phenotype (SASP) [43]. SASP acts in a cell-
autonomous paracrine manner and has both a bright side,
favoring senescence in normal or low-grade preneoplastic
cells, as well as a dark side, facilitating evasion of senescence
inhighgradepreneoplasticorcancerouscells[44].TheSASP
involves a number of inﬂammatory cytokines, such as IL-
6 and chemokine IL-8, which constitute two of its promi-
nent components [43]. It has been demonstrated that the
proinﬂammatory cytokines IL-6 and IL-8 are upregulated by
persistent DNA Damage Response (DDR) activation which
in turn boost the DDR signaling pathway forming a positive
feedback loop [43]. Of note, IL-6 and IL-8 are known to play4 Journal of Biomedicine and Biotechnology
Table 1: Potential pro- and antitumorigenic roles of cytokines.
Cytokine Protumorigenic role Antitumorigenic role Unspeciﬁed yet role
in tumorigenesis References
IL-1 (α and β)
Tumor growth, invasion and
metastasis, mainly through the
action of IL-1β in promoting
local inﬂammatory responses
as well as angiogenesis.
Restraint of tumor growth
through activation of innate
and speciﬁc immune eﬀector
mechanisms mainly through
the action of IL-1α.
[17]
IL-2
( i )S t i m u l a t e sg r o w t h ,
diﬀerentiation, and survival of
cytotoxic T cells
(ii) Induces diﬀerentiation
and proliferation of NK cells
[53]
IL-3
Stimulates the
diﬀerentiation and
growth of
multipotent
hematopoietic stem
cells
[54]
IL-4
(i) Decreases the production
of Th1 cells, macrophages,
and IFN-gamma
(ii) Has been shown to drive
dediﬀerentiation, mitogenesis
and metastasis in
rhabdomyosarcoma
Stimulation of activated B-cell
a n dT - c e l lp r o l i f e r a t i o n ,a n d
diﬀerentiation of CD4+
T-cells into Th2 cells
IgE and class II
MHC expression on
Bc e l l s
[55]
IL-5
( i )S t i m u l a t e sBc e l l
growth
(ii) Stimulates
eosinophil growth
and function
[56]
IL-6
(i) Promotion of tumor cell
proliferation and inhibition of
their apoptosis through
activation of STAT-3.
(ii) Facilitation of senescence
evasion in high-grade
preneoplastic or cancerous
cells through mechanisms of
SASP.
(iii) Favours metastasis
(i) Mediator of the acute
phase response
(ii) Induction of senescence in
normal or low grade
preneoplastic cells.
[25, 44]
IL-7 Stimulates proliferation of B
cells, T cells, and NK cells
Stimulates the
diﬀerentiation of
multipotent
hematopoietic stem
cells
[57]
IL-8
Signiﬁcant role in tumor
growth, angiogenesis,
epithelial to mesenchymal
transition (EMT) and
invasiveness
(i) Induction of chemotaxis in
its target cells (neutrophils,
granulocytes)
(ii) Induction of senescence in
normal or low-grade
preneoplastic cells.
[43, 44]
IL-9
(i) Potential role in
tumorigenesis due to
antiapoptotic and growth
factor activities
(ii) Deregulated IL-9 response
may lead to malignant
transformation through
Jak/STAT activation
Regulation of
hematopoietic cells [58]Journal of Biomedicine and Biotechnology 5
Table 1: Continued.
Cytokine Protumorigenic role Antitumorigenic role Unspeciﬁed yet role in
tumorigenesis References
IL-10
Potential tumor promoting
activity through activation of
STAT3 and consequent
upregulation of BCL-2 or
BCL-XL antiapoptotic genes.
(i) Enhances B-cell survival,
proliferation, and antibody
production.
(ii) Inhibition of tumor
development and progression
through inhibition of NF-κB
activation, TNF-α,I L - 6 ,a n d
IL-12.
(iii) Suppression of angiogenesis
through inhibition of the tumor
stroma.
[10, 59]
IL-11
(i) Regulator of
haematopoiesis
(ii) Stimulation of
megakaryocyte
maturation
[60]
IL-12
( i )S t i m u l a t e st h eg r o w t ha n d
function of T cells
(ii) Stimulates the production of
IFN-γ,T N F - α
(iii) Induces cell-mediated
immune responses
(iv) Exhibits antiangiogenic
activity
[61]
IL-13 Induces IgE secretion [62]
IL-14
Regulates the growth
and proliferation of B
cells
[63]
IL-15
( i )S t i m u l a t e sg r o w t h ,
diﬀerentiation and survival of
cytotoxic T cells
(ii) Induces diﬀerentiation and
proliferation of NK cells
[53]
IL-16
Chemoattractant for certain
immune cells expressing the cell
surface molecule CD4.
[64]
IFN-γ
(i) Produced by cytotoxic CD8+
and CD4+ Th1 T cells
(ii) Exhibits an overall signiﬁcant
tumor inhibitory action.
[1, 7]
TGF-β Tumor promoting role at the
late stages of carcinogenesis
Tumor suppressive role in the
beginning of carcinogenesis [40]
OPN
Implicated in enhanced
metastasis and invasion of
tumor cells
[68]
CCL2
(i) Induces the recruitment of
macrophages
(ii) Induces angiogenesis and
matrix remodeling
(iii) Promotes prostate cancer
cell proliferation, migration,
invasion, and survival
[69]
CCL21
(i) Immune-mediated antitumor
response (chemoattraction of B
cells and NK cells to the lymph
nodes)
(ii) Angiostatic eﬀect
[70, 71]6 Journal of Biomedicine and Biotechnology
Table 1: Continued.
Cytokine Protumorigenic role Antitumorigenic role Unspeciﬁed yet role
in tumorigenesis References
CCL16 Augments the cytotoxic
activities of eﬀector T cells [72]
CXCL12
(i) Suppress antitumor
immunity in the tumor
microenvironment
(ii) Regulates traﬃcking of
immature and maturing
immune cells
(iii) Promotes angiogenesis
(iv) Facilitates metastasis
[73]
NK cells: Natural Killer cells; IgE: Immunoglobulin E; MHC: Major Histocompatibility Complex; OPN: Osteopontin.
a signiﬁcant role in tumor growth, angiogenesis, epithelial to
mesenchymal transition (EMT), and invasiveness [43, 45].
The aforementioned part indicates that the IL-6/IL-8 duet
seemstoex ertbothanti-aswellasprotumorigenicfunctions.
IL-1 proinﬂammatory cytokine (both α and β forms) is
also a SASP component secreted at lower levels compared
to IL-6/IL-8 and interestingly IL-1α regulates the signaling
network that leads to the expression of the latter duet [46].
4.Cytokine-MediatedGrowthSignaling,
Replication Stress, andGenomicInstability
Recently it has been proposed that genomic instability is
an evolving hallmark of cancer and Hanahan and Weinberg
(2011) established that it constitutes an enabling characteris-
tic for the acquisition of the essential functions (hallmarks)
of a cancerous cell [6, 47]. Genomic instability is present
in most human cancer types and has various forms. The
most frequently occurring one is chromosomal instability
(CIN) which involves structural and numerical chromo-
somal changes that occur in cancer cells over time [47].
Another common form is microsatellite instability (MIN or
MSI) which is caused by alterations in DNA mismatch repair
genes and leads to changes in the number of oligonucleotide
repeats in microsatellite sequences [47]. Genomic instability
is observed from early stages of cancer development, even
before the acquisition of the cell’s cancerous phenotype [48].
CIN is more frequently observed in human cancers com-
pared to MIN and this might be explained by the formation
of double-strand breaks (DSBs) in precancerous lesions and
cancers according to the oncogene-induced DNA damage
model [49].
Recent studies have unveiled the potential eﬀects of
enhanced growth signalling in age and/or age-related dis-
eases, such as cancer. The proposed mechanism involves
the induction of DNA replication stress which leads to the
formation of DNA double-strand breaks (DSBs), favouring
genomic instability and tumorigenesis [50, 51]. Indeed, up-
regulation of growth-signalling pathways in all eukaryotes
has been shown to impact cellular processes leading to
increased oxidative DNA damage and replication stress in
a correlative manner. DNA replication stress may occur
by any mechanism causing slow progression or stalling of
DNA replication forks and, as a result, compromise proper
DNA replication [50]. The structural characteristics of the
replicating DNA strands are greatly responsible for the
induction of replication stress-induced DNA damage, as any
lesions of the single-strand templates within the unfolded
DNA at the sites of the replication forks subsequently cause
DSBs. Consequently, the genetic sequence harbouring DSBs
isrenderedhighlysusceptibletoseriousgenerearrangements
and genomic instability. Contemporary studies have clearly
shown the activation of the replication stress-induced DNA
damageresponse(DDR)pathwayattheearlieststagesofcan-
cerdevelopmentunderlyingitssigniﬁcanceincarcinogenesis
[48, 52].
Severalcytokinesexhibitgrowthfactoractivity.Themost
signiﬁcant cytokines to date designated as growth factors
are the following: Epidermal Growth Factor (EGF), Platelet-
Derived Growth Factor (PDGF), Fibroblast Growth Factor
(FGF), TGF-α,T G F - β, Erythropoietin, Insulin-Like Growth
Factor1(IGF-1),Insulin-LikeGrowthFactor2(IGF-2),IL-1,
IL-2,IL-6,IL-8,TNF-α,TNF-β,INF-γ,andColonyStimulat-
ing Factors (CSFs) (Table 1). Within this context a potential
mechanism linking persistent chronic inﬂammation with
carcinogenesis is through the activity of growth-promoting
cytokines in the inﬂamed tissue. It has been previously
shown that the injection of adenoviral vectors expressing a
cocktailofgrowthfactors(includingﬁbroblastgrowthfactor,
stem cell factor, and endothelin-3) in human skin xenografts
causes allelic imbalance in common fragile sites (CFSs),
suggesting the formation of DSBs through replication stress
[48]. In accordance with this, the presence of several growth-
promoting cytokines within the inﬂammatory milieu for
a prolonged period of time may induce replication stress
and subsequent DSBs (Figure 1). In a rat silica model
of inﬂammation-induced lung cancer the presence of the
DNA damage response marker γH2AX was observed from
early hyperplastic tissues, in bronchiolar hyperplasia, which
supports the previous statement [74]. In another study
the addition of IGF-1 or IGF-2 in human peripheral
bloodlymphocytesalreadyincubatedwithbleomycinfurther
increased the expression of p53 and the rate of chromosome
aberrations, suggesting potential implication of DDR acti-
vation [75].Overall, these ﬁndings indicate a potential roleJournal of Biomedicine and Biotechnology 7
iNOS
Growth
factors
FGFs, TGF-β,
IL-1, IL-2, IL-6,
IL-8, TNF-α,
TNF-β
R
RONS
Cytokine pool
IL-1β, IL-6,
TNF-α, IFN-γ,
OPN
NAD(P)H
oxidase
Signaling pathways
Genomic instability
e.g., EGF, PDGF,
(e.g., MAPK, JAK-STAT3, NFκB, AP1)
Figure 1:Schematicpresentationoftheproposedmechanismbywhichcytokinesmaypromotegenomicinstabilityinchronicinﬂammatory
conditions. Cytokines with growth factor activity may promote replication stress favouring the formation of DSBs. In addition, several
cytokines induce the formation of RONS which in turn may cause DNA damage, including DNA cross-links, single- or double-strand
breaks, and oxidative DNA damage with formation of 8-hydroxydeoxyguanosine (8-OHdG). Both mechanisms may provide a mechanism
linkingcytokineexpressionwithgenomicinstability.MAPK:mitogen-activatedproteinkinase;JAK-STAT3:Januskinase-SignalTransducer
and Activator of Transcription 3; NF-κB: Nuclear Factor-κB; AP-1: Activator Protein 1; OPN: Osteopontin; R: Receptor; RONS: Reactive
Oxygen/Nitrogen Species; NAD(P)H oxidase: Nicotinamide Adenine Dinucleotide Phosphate-oxidase; iNOS: inducible Nitric Oxide
Synthase.
of cytokines with growth factor activity in the promotion of
genomic instability through replication stress-induced DNA
damage.
5. CytokinesandOxidative/NitrosativeStress
Reactive Oxygen and Nitrogen Species (RONS) are the free
radical forms of oxygen and nitrogen, respectively. Free
radicals contain one or more unpaired electrons rendering
them highly reactive molecular metabolites [76, 77]. RONS
a r ep r o d u c e db ye n d o g e n o u sa sw e l la se x o g e n o u ss o u r c e s .
Endogenous sources include metabolic reactions, such as
electron transport reactions in the mitochondrial respiratory
chain, metal reactions, and cells of the innate immune
system,suchasneutrophilsandmacrophages,duringinﬂam-
matory responses [33, 77]. Exogenous sources include atmo-
sphere pollutants, ionizing and nonionizing radiation, sev-
eral carcinogenic compounds, and metal ions [77].
The most commonly generated Reactive Oxygen Species
(ROS) in cells are the superoxide anion (O
−￿
2 ), hydrogen
peroxide (H2O2), and the hydroxyl radical (OH￿). The
NADPH oxidase is an enzyme that plays the role of an
electron donor and generates O
−￿
2 from oxygen in the body
[78]. This enzyme can also lead to the production of H2O2
on neutrophil membranes [77]. NADPH oxidase exists in
both phagocytes and nonphagocytes and has ﬁve known
isoforms (NOX 1–5) as well as two reported related enzymes
(DUOX1-2)todate[78].Nitricoxide(NO￿)isareactiv efree
radical that generates additional Reactive Nitrogen Species
(RNS) and is more stable in a hypoxic environment than in
normal oxygen tension conditions [33,77].NO￿ is generated
by the enzyme nitric oxide synthase (NOS) during the
metabolization of L-arginine to citrulline [77, 79]. This
enzyme exists in three isoforms in mammalian cells which
consist of the neuronal (n)NOS, the endothelial (e)NOS,
and the inducible (i)NOS [22, 80]. The nNOS and eNOS
isoforms are constitutively expressed and produce low levels
of NO￿, while iNOS produces high levels of nitric oxide
only upon inﬂammatory stimuli [22, 33]. The nNOS and
eNOS isoforms generate NO￿ with a neurotransmitting
and vasodilating role, respectively, while the iNOS isoform
produces NO￿ as a mediator of the inﬂammatory response
[33, 81].
RONS play a dual role in the cell, at low concentrations
they are beneﬁcial exhibiting several physiological functions
in cellular responses (such as cellular signaling pathways and
mitogenic responses), whereas at high concentrations they
are detrimental for its integrity [77, 82, 83]. Excessive ROS
and RNS production leads to oxidative and nitrosative stress,
respectively. In order to counteract the harmful eﬀects of
free radicals the cell has evolved several defense mechanisms.
These mechanisms involve the action of enzymatic, such as
superoxide dismutase (SOD), catalase, glutathione peroxi-
dase(GPx),andnonenzymaticantioxidants,suchasVitamin
C and E, glutathione, carotenoids, and ﬂavonoids [33, 77].
As mentioned earlier, RONS can be released by immune
cellsasaresponsetoaninﬂammatorystimulus.Interestingly,
during an inﬂammatory response phagocytic cells can8 Journal of Biomedicine and Biotechnology
directly produce RONS whereas in nonphagocytic cells
their production is triggered by proinﬂammatory cytokines,
such as IL-1 and IL-6 [22, 84]. In 1997, it was the ﬁrst
time reported that speciﬁc proinﬂammatory cytokines, IL-
1, TNF-α,a n dI F N - γ, generate ROS in nonphagocytic cells
[77, 85]. Later on, it was shown that IFN-γ,T N F - α,a n dI L -
1β promote ROS through the induction of NOX1 in colon
epithelium cells [78]. IFN-γ also increases the expression
level of the NOX2 isoform of NADPH oxidase in human
macrophages and neutrophils as well as the expression
of its DUOXA2-related enzyme in airway epithelial cells
[78]. The anti-inﬂammatory cytokine TGF-β induces NOX4
expression in many cell types, such as cardiac ﬁbroblasts,
smooth muscle cells, and hepatocytes. IL-4 and IL-13 anti-
inﬂammatory cytokines augment the expression level of
DUOXA1 enzyme in airway epithelial cells [78, 86–89].
Recently, it was shown that the inﬂammatory mediator
leukotriene B4 (LTB4) induces NOX1 in human mast cells
[90]. Finally IL-1, TNF-α,a n dI F N - γ proinﬂammatory
cytokines stimulate the production of iNOS, which is
inducibly expressed in macrophages, and thus contribute to
the formation of nitric oxide as well as RNS [33, 91]. Overall,
bothpro-andanti-inﬂammatorycytokineshavebeenshown
to contribute to RNOS production through the induction
of NADPH oxidase and iNOS activity. Interestingly, it has
beenshownthattheproinﬂammatorycytokinesseemtoplay
a tumor promoting role while anti-inﬂammatory cytokines
exert an antioncogenic function [22]. The latter leads to the
suggestion of a potential link between inﬂammation, free
radical-induced stress, and carcinogenesis.
6.FreeRadicalsand
Inﬂammatory-InducedCarcinogenesis
ReactiveOxygenandNitrogenSpecies(RONS)canbegener-
ated during inﬂammatory responses, and interestingly some
inﬂammation-associated cancers are linked to oxidative
and nitrosative stress. Examples include colorectal cancer
provoked after active chronic colitis as well as lung, pan-
creatic, and esophageal cancers provoked after persistent
inﬂammation of the bronchi, pancreas, and oesophagus
respectively [33, 92–95]. In the previously mentioned cancer
types either excessive free radical production or defective
antioxidant mechanisms or both of these were observed.
Inﬂammation-mediated ROS production can trigger
carcinogenesiseitherdirectlyorindirectly [33].Directeﬀects
involve the formation of DNA cross-links, single- or double-
strand breaks leading to mutations in oncogenes and tumor
suppressor genes and ultimately to genomic instability
(Figure 1)[ 33, 77, 84, 96]. An example is the formation of an
extremely reactive free radical species during inﬂammatory
response, named peroxynitrite anion (ONOO−), produced
by the reaction between the superoxide anion and nitric
oxide, which can create DNA fragmentation [77]. Addition-
ally, the hydroxyl radical is known to cause damage to the
purine and pyrimidine bases as well as the deoxyribose back-
bone [77, 97]. The most known DNA damage indicative of
oxidativestressistheformationof8-hydroxydeoxyguanosine
(8-OHdG) that is generated by the oxidative attack of
OH￿ in the cell DNA [33]. Free radical production during
inﬂammatory process can indirectly lead to carcinogen-
esis via ROS-mediated activation of signalling pathways
(Figure 1)[ 33]. An important example is the involvement
of oxidative stress in the activation of the transcription factor
NF-κB which in turn may display a protumorigenic eﬀect,
as mentioned earlier. Low to mild levels may lead to NF-
κB expression, since H2O2 has been shown to degrade the
IκBα subunit, whereas high levels of oxidative stress in the
cells may cause inhibition of NF-κB expression [33, 98, 99].
Interestingly, growing evidence supports the fact that ROS
actassecondmessengersintheNF-κBactivationthroughthe
proinﬂammatory cytokines TNF and IL-1 [33, 77]. It is also
worthwhile mentioning that iNOS can be induced by several
stimuli, including cytokines as well as NF-κB transcription
factor [22, 100]. Free radicals and cytokines can both either
induce or become induced by NF-κB and their generation
by tumor cells in inﬂammation-induced cancers can actually
createapositivefeedbackloopfortheirownproduction.The
inﬂammatory microenvironment that develops around the
tumors leads to additional production of cytokines and free
radicals, which in turn favours the carcinogenesis process
[22]. In addition, oxidative stress can cause MIN by reducing
the enzymatic activity and expression of the DNA mismatch
repair genes mutS homologs 2 and 6 [22, 33]. Free radicals
lead to gene silencing of the DNA mismatch repair gene
hMLH1 via hypermethylation induced by overexpression of
DNA methyltransferases [22, 33].
Cancer development involves three stages, initiation,
promotion, and progression, and oxidative stress is involved
inalltheprevious.Intheinitiationstage,ROSpromoteDNA
damage, such as 8-OHdG formation, that may subsequently
lead to gene mutations [33, 77]. During the promotion
stage, low levels of oxidative stress can cause modiﬁcations
in second messenger systems and promote cell division and
proliferation [33, 77]. Finally in the progression stage, ROS
can create additional genetic alterations fuelling cancer cells
with further evolutionary advantages [33, 77]. Overall, the
action of RONS is dosedependent within a particular cell
context often with tumor-promoting activity in low levels,
whereas in high levels they may raise the antitumor barriers,
namely, apoptosis and senescence [33].
7.FuturePerspectives
Cytokines display pleiotropic actions ranging from tumor-
protective to tumor-promoting activity in a spatial and tem-
poral manner. The fact that certain cytokines display growth
factoractivityaswellastheabilitytoproduceRONSsuggests
that they may promote genomic instability in chronic
inﬂammatory conditions. This is particularly signiﬁcant
taking into account the central role of cytokines as mediators
of inﬂammation, a knowledge that can be exploited in future
cancer therapeutic strategies. IL-2 and IL-15 are currently
tested for their therapeutic potential in cancer [53]. It has
been shown that IL-15 plays an important role in the
antitumor eﬃcacy of combination therapy with ImatinibJournal of Biomedicine and Biotechnology 9
Mesylate (IM), a tyrosine kinase inhibitor, and IL-2 in a
mouse lung metastasis model, inducing a CCL2-dependent
chemoattraction of IFN-producing killer dendritic cells
(IKDCs) in the tumor microenvironment [101]. The latter
ﬁnding has been exploited therapeutically by launching
phase I clinical trial targeting IM-resistant gastrointestinal
sarcomas and TRAIL-sensitive cancers. CCL2 serves as
another paradigm of translation of molecular biology to
clinical practice [69, 102]. Although there are conﬂicting
data regarding the role of CCL2 in carcinogenesis, it seems
that it promotes prostate cancer development. Therefore, a
neutralizing antibody against CCL2 is under clinical trials in
prostate cancer. Conclusively, elucidation of the molecular
mechanisms implicated in tumor-host interactions may
provide new insight in understanding tumor development as
well as provide additional future prospects for more eﬀective
and targeted cancer therapy and prevention.
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